The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia

Anderson Brito da Silva, Jane Pennifold, Ben Henley, Koustav Chatterjee, David Bateman, Roger W. Whittaker, Abhijit Joshi, Hrishikesh Kumar, Claire Nicholson, Mark R. Baker, Stuart D. Greenhill, Richard Walsh, Stefano Seri, Roland S.G. Jones, Gavin L. Woodhall, Mark O Cunningham

Research output: Contribution to journalArticlepeer-review

3 Citations (SciVal)

Abstract

Focal cortical dysplasia (FCD) is one of the most common malformations causing refractory epilepsy. Dysregulation of glutamatergic systems plays a critical role in the hyperexcitability of dysplastic neurons in FCD lesions. The pharmacoresistant nature of epilepsy associated with FCD may be due to a lack of well-tolerated and precise antiepileptic drugs that can target glutamate receptors. Here, for the first time in human FCD brain slices, we show that the established, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, perampanel has potent antiepileptic action. Moreover, we demonstrate that this effect is due to a reduction in burst firing behavior in human FCD microcircuits. These data support a potential role for the treatment of refractory epilepsy associated with FCD in human patients.

Original languageEnglish
Pages (from-to)488-495
Number of pages8
JournalEpilepsia Open
Volume7
Issue number3
Early online date11 May 2022
DOIs
Publication statusPublished - 30 Sept 2022

Bibliographical note

Funding Information:
This work has been supported by investigator‐initiated grants from Eisai (MOC and GLW), Birmingham Children's Hospital Charities grant BCHRF349 (SS, GLW) and Aston Brain Centre (GLW), the Wellcome Trust/EPSRC (102037; RGW and MOC), and a CAPES‐funded (Brazil) PhD studentship (BEX‐0437‐14‐0; ABDS, RGW, and MOC). Editorial support, under the direction of the authors, was provided by Stephanie Agbu, PhD, of CMC AFFINITY, a division of Complete Medical Communications Inc, Hackensack, NJ, USA, funded by Eisai Inc, in accordance with Good Publication Practice (GPP3) guidelines.

Funding Information:
This work has been supported by investigator-initiated grants from Eisai (MOC and GLW), Birmingham Children's Hospital Charities grant BCHRF349 (SS, GLW) and Aston Brain Centre (GLW), the Wellcome Trust/EPSRC (102037; RGW and MOC), and a CAPES-funded (Brazil) PhD studentship (BEX-0437-14-0; ABDS, RGW, and MOC). Editorial support, under the direction of the authors, was provided by Stephanie Agbu, PhD, of CMC AFFINITY, a division of Complete Medical Communications Inc, Hackensack, NJ, USA, funded by Eisai Inc, in accordance with Good Publication Practice (GPP3) guidelines.

Publisher Copyright:
© 2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Keywords

  • AMPA
  • epilepsy
  • focal cortical dysplasia
  • glutamate
  • perampanel

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia'. Together they form a unique fingerprint.

Cite this